F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Biological basis for functional cure of chronic hepatitis B
TL;DR: Novel treatments both targeting directly and indirectly ccc DNA, and newer technologies emerge that could potentially allow the destruction of cccDNA, exciting new possibilities for curative therapies are discussed.
Journal Article
Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program
Christophe Hézode,Victor de Ledinghen,Hélène Fontaine,Fabien Zoulim,Pascal Lebray,Nathalie Boyer,Dominique Larrey,Christine Silvain,Danielle Botta-Fridlund,Vincent Leroy,Marc Bourlière,Louis d’Alteroche,Isabelle Fouchard-Hubert,Dominique Guyader,Isabelle Rosa,Eric Nguyen-Khac,Vincent Di Martino,Fabrice Carrat,L. Fedchuk,Raoudha Akremi,Yacia Bennai,Jean-Pierre Bronowicki +21 more
Journal ArticleDOI
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B
Teresa Santantonio,Massimo Fasano,Sandra Durantel,Luc Barraud,Manuela Heichen,A. Guastadisegni,Giuseppe Pastore,Fabien Zoulim +7 more
TL;DR: Although most patients showed virological breakthrough because of the well known rtA181V/T and rtN236T substitutions, more complex patterns were also found.
Journal ArticleDOI
A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus.
TL;DR: The patient appeared to have made a quasi-monoclonal humoral response to the y epitope, which means the virus could replicate, despite the high levels of anti-HBs.
Journal ArticleDOI
Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.
TL;DR: For patients coinfected with HIV, hepatitis B treatment options that aim to reduce the risk of HBV mutations from emerging must be seriously considered, not only from clinical but also public health perspectives.